Cure One Cure Many Award

The American Brain Foundation’s Cure One, Cure Many Award seeks to attract the best minds in brain disease research to advance research that addresses key knowledge gaps that cut across brain diseases. The award brings together funders to advance progress on large-scale, cross-cutting research topics.

The specific priority areas for this award are announced periodically.

Improving Diagnosis for Lewy Body Dementia

In partnership with the Alzheimer’s Association, The Michael J. Fox Foundation for Parkinson’s Research, and the American Academy of Neurology, the American Brain Foundation is seeking to accelerate progress in the diagnosis of Lewy body dementia (LBD). LBD is the most common form of dementia after Alzheimer’s disease.

Currently, LBD can only be definitively diagnosed with a brain autopsy after death. As a result of a delay in diagnosis and misdiagnosis, people with LBD and their caregivers endure daily challenges and uncertainty. The goal of the 2022 Cure One, Cure Many Award is to attract the best minds in brain disease research to find a biomarker (diagnostic test) for LBD.